AnaptysBio Inc【ANAB】株式ニュース

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment...

Form EFFECT - Notice of Effectiveness

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Anaptys Announces Participation in November and December Investor Conferences

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Monksdream 3月前

ANAB definite uptrend

👍️0

gfp927z 3年前

HighPeaks, The NY Times article was high profile, but the connection to ANAB isn't readily apparent.

Even with the partial sale/monetization of the revenue stream from dostarlimab in December, the drug is also being studied by Glaxo for other cancer types (endometrial, non-small cell lung, ovarian, and mismatch repair deficient solid tumors). One question to answer is whether the monetization deal with Sagard was only for colorectal, or for all the indications? Probably for all, but I'll have to do more research.

ANAB has numerous other programs and a large pile of cash, so looks interesting. But investing in biotech requires a ton of research, but even then you still don't know what you have, and landmines are everywhere. Better to invest in 'what you know', as Buffett recommends :o)

---

👍️0

HighPeaks 3年前

Thanks TP. Yeah this has the potential to really be a big mover. So surprised no one has made the connection between this potential miracle drug and $ANAB receiving royalties on it(as it’s originator). GSK is the collaborator who has just commercialized it but it’s ANAB invention.

👍️0

tedpeele 3年前

Tremendous find HighPeaks. .You have been early on quite a few big movers. I'm thinking this is yet another one.

Will be watching this closely...thanks.

👍️0

HighPeaks 3年前

According to this link ANAB gets 8-25% royalties from Dostarlimab. This drug has recently shown phenomenal results in a trial at Memorial Sloan Kettering Hospital. All patients fully recovered from rectal cancer.
https://www.globenewswire.com/fr/news-release/2020/10/26/2114250/0/en/AnaptysBio-and-GlaxoSmithKline-Amend-Strategic-Immuno-Oncology-Collaboration.html

👍️0

TFMG 4年前

$ANAB | #Anaptysbio Spikes After Drug Designation

Nice spike in the afterhours session, lets hope we
can get some continuation tomorrow.
Target $29.00 to Fib Golden Pocket
Also a very large gap to fill at $35.00
AnaptysBio gets orphan drug designation of imsidolimab for pustular psoriasis
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.

👍️0

LoveItInBishop 5年前

RSI @ 16. laughable. Zacks has positive take. https://finance.yahoo.com/news/anaptysbio-enters-oversold-territory-135501475.html

👍️0

ClayTrader 5年前

* * $ANAB Video Chart 11-13-19 * *

Link to Video - click here to watch the technical chart video

👍️0

ClayTrader 5年前

* * $ANAB Video Chart 11-08-19 * *

Link to Video - click here to watch the technical chart video

👍️0

waterchaser 5年前

LOL! Twitter PnD. Buyer beware.

👍️0

420man 5年前

Once the real bounce starts it will be fast....

This will bounce..... 15 AH

👍️0

RJ Trotts 5年前

trying to bounce back over $11, hoping for more

This stock is making noise! Bought in Sept $ANAB

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

AnaptysBio Inc (ANAB)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

ANAB ニュース

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Form EFFECT - Notice of Effectiveness

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Anaptys Announces Participation in November and December Investor Conferences

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ANAB Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

AnaptysBio Inc (ANAB) ニュース

AnaptysBio Inc (ANAB)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

ANAB ニュース

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Form EFFECT - Notice of Effectiveness

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Anaptys Announces Participation in November and December Investor Conferences

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ANAB Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手